NCT01410916View on ClinicalTrials.gov

Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

198

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

January 31, 2012

Study Completion Date

June 30, 2012

Conditions
Shiga-like Toxin-producing Escherichia Coli
Interventions
DRUG

Eculizumab (Soliris®)

Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously

Trial Locations (22)

20246

Hamburg

22291

Hamburg

22359

Hamburg

23538

Lübeck

24939

Flensburg

26133

Oldenburg

27574

Bremerhaven

27793

Wildeshausen

28177

Bremen

30625

Hanover

33615

Bielefeld

33617

Bielefeld

37075

Göttingen

39120

Magdeburg

45147

Essen

48149

Münster

50937

Cologne

53127

Bonn

76133

Karlsruhe

80804

Munich

81377

München

89081

Ulm

Sponsors
All Listed Sponsors
lead

Alexion Pharmaceuticals, Inc.

INDUSTRY